Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Mara Dottore"'
Autor:
Sophie E. Broughton, Timothy R. Hercus, Tracy L. Nero, Winnie L. Kan, Emma F. Barry, Mara Dottore, Karen S. Cheung Tung Shing, Craig J. Morton, Urmi Dhagat, Matthew P. Hardy, Nicholas J. Wilson, Matthew T. Downton, Christine Schieber, Timothy P. Hughes, Angel F. Lopez, Michael W. Parker
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-15 (2018)
The N-terminal domain (NTD) of interleukin-3 receptor α-subunit (IL3Rα) is involved in IL-3 recognition but the underlying mechanism is unknown. Here, the authors present crystal structures of the IL3Rα complex and provide biochemical evidence tha
Externí odkaz:
https://doaj.org/article/a177e8976263487282e8d1895527256b
Autor:
Nicole L. Wittwer, Gabriela Brumatti, Ceilidh Marchant, Jarrod J. Sandow, Melanie K. Pudney, Mara Dottore, Richard J. D'Andrea, Angel F. Lopez, Paul G. Ekert, Hayley S. Ramshaw
Publikováno v:
Blood Advances, Vol 1, Iss 15, Pp 1067-1079 (2017)
Abstract: High expression of the α chain of the interleukin-3 receptor (IL-3Rα; CD123) is a hallmark of acute myeloid leukemia (AML) leukemic stem cells (LSCs). Elevated CD123 expression is part of the diagnostic immunophenotyping of myeloid leukem
Externí odkaz:
https://doaj.org/article/06a3c0aaf2114e6a92cf5ba3f7cf2246
Autor:
Sophie E. Broughton, Timothy R. Hercus, Matthew P. Hardy, Barbara J. McClure, Tracy L. Nero, Mara Dottore, Huy Huynh, Hal Braley, Emma F. Barry, Winnie L. Kan, Urmi Dhagat, Pierre Scotney, Dallas Hartman, Samantha J. Busfield, Catherine M. Owczarek, Andrew D. Nash, Nicholas J. Wilson, Michael W. Parker, Angel F. Lopez
Publikováno v:
Cell Reports, Vol 8, Iss 2, Pp 410-419 (2014)
Interleukin-3 (IL-3) is an activated T cell product that bridges innate and adaptive immunity and contributes to several immunopathologies. Here, we report the crystal structure of the IL-3 receptor α chain (IL3Rα) in complex with the anti-leukemia
Externí odkaz:
https://doaj.org/article/06924e2c5a1a4bf8928942626539913b
Autor:
Timothy R Hercus, Emma F Barry, Mara Dottore, Barbara J McClure, Andrew I Webb, Angel F Lopez, Ian G Young, James M Murphy
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e74376 (2013)
Human interleukin-3 (hIL-3) is a polypeptide growth factor that regulates the proliferation, differentiation, survival and function of hematopoietic progenitors and many mature blood cell lineages. Although recombinant hIL-3 is a widely used laborato
Externí odkaz:
https://doaj.org/article/dfae7e17c9a84becbef847d834d58d54
Autor:
Winnie L. Kan, Urmi Dhagat, Kerstin B. Kaufmann, Timothy R. Hercus, Tracy L. Nero, Andy GX. Zeng, John Toubia, Emma F. Barry, Sophie E. Broughton, Guillermo A. Gomez, Brooks A. Benard, Mara Dottore, Karen S. Cheung Tung Shing, Helena Boutzen, Saumya E. Samaraweera, Kaylene J. Simpson, Liqing Jin, Gregory J. Goodall, C. Glenn Begley, Daniel Thomas, Paul G. Ekert, Denis Tvorogov, Richard J. D'Andrea, John E. Dick, Michael W. Parker, Angel F. Lopez
Publikováno v:
Cancer Discovery.
Leukemia stem cells (LSC) possess distinct self-renewal and arrested differentiation properties that are responsible for disease emergence, therapy failure and recurrence in acute myeloid leukemia (AML). Despite AML displaying extensive biological an
Autor:
Denis Tvorogov, Chloe A L Thompson‐Peach, Johannes Foßelteder, Mara Dottore, Frank Stomski, Suraiya A Onnesha, Kelly Lim, Paul A B Moretti, Stuart M Pitson, David M Ross, Andreas Reinisch, Daniel Thomas, Angel F Lopez
Publikováno v:
EMBO reports. 23(4)
Refereed/Peer-reviewed Calreticulin (CALR) is recurrently mutated in myelofibrosis via a frameshift that removes an endoplasmic reticulum retention signal, creating a neoepitope potentially targetable by immunotherapeutic approaches. We developed a s
Autor:
Gregory J. Goodall, Kaylene J. Simpson, Winnie L. Kan, Guillermo A. Gomez, John Toubia, Urmi Dhagat, Paul G Ekert, Daniel Thomas, Emma F Barry, Andy G.X. Zeng, Mara Dottore, Erwin M. Schoof, Denis Tvorogov, Sophie E. Broughton, C. Glenn Begley, Tracy L. Nero, Karen S. Cheung Tung Shing, Richard J D'Andrea, Kerstin B. Kaufmann, John E. Dick, Michael W. Parker, Timothy R. Hercus, Angel F. Lopez, Brooks Benard
Publikováno v:
SSRN Electronic Journal.
Leukemia stem cells (LSC) possess distinct self-renewal and arrested differentiation properties that are responsible for disease emergence, therapy failure and recurrence in acute myeloid leukemia (AML). Pleiotropic cytokines like interleukin (IL)-3
Autor:
Suraiya A Onnesha, Frank C. Stomski, Mara Dottore, Denis Tvorogov, Angel F. Lopez, Johannes Foßelteder, David M. Ross, Andreas Reinisch, Chloe Al Thompson-Peach, Kelly Sy Lim, Daniel Thomas
Publikováno v:
Blood. 138:3597-3597
Introduction: Mutations within the gene encoding calreticulin (CALR) are the second most common genetic aberration associated with primary myelofibrosis (PMF), observed in 70% of non-JAK2 V617F cases. Importantly, patients with CALR mutations do not
Autor:
Mara Dottore, Veronika Rayzman, Michael J. Wilson, Catherine M. Owczarek, Matthew P. Hardy, Timothy R. Hercus, Gino Vairo, Gail M. Gauvreau, Nicholas J. Wilson, Barbara J. McClure, Angel F. Lopez, Laura McMillan, Kirsten Edwards, Roma Sehmi, Steven G. Smith, Urmi Dhagat, Louis Fabri, Michael W. Parker, Hal Braley, Con Panousis, Andrew D. Nash
Publikováno v:
mAbs
The β common-signaling cytokines interleukin (IL)-3, granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-5 stimulate pro-inflammatory activities of haematopoietic cells via a receptor complex incorporating cytokine-specific α and share
Autor:
Frank C. Stomski, Winnie L. Kan, Mara Dottore, Ravindra Majeti, Vinay Tergaonkar, Timothy P. Hughes, Jeffrey J. Babon, Denis Tvorogov, Daniel Thomas, Nicholas P. D. Liau, Angel F. Lopez, Maya Lathi, Timothy R. Hercus, Michael W. Parker, David M. Ross, Emma F Barry
Publikováno v:
Science Advances
Pathological drug withdrawal syndrome is linked to accumulation of JAK2 phosphorylation in V617F myelofibrosis.
Treatment of patients with myelofibrosis with the type I JAK (Janus kinase) inhibitor ruxolitinib paradoxically induces JAK2 activati
Treatment of patients with myelofibrosis with the type I JAK (Janus kinase) inhibitor ruxolitinib paradoxically induces JAK2 activati